Esperion Therapeutics, Inc. (0IIM.L)

USD 0.99

(0.07%)

Revenue Summary of Esperion Therapeutics, Inc.

  • Esperion Therapeutics, Inc.'s latest annual revenue in 2023 was 116.33 Million USD , up 54.14% from previous year.
  • Esperion Therapeutics, Inc.'s latest quarterly revenue in 2024 Q2 was 73.83 Million USD , down -46.39% from previous quarter.
  • Esperion Therapeutics, Inc. reported a annual revenue of 75.47 Million USD in annual revenue 2022, down -3.79% from previous year.
  • Esperion Therapeutics, Inc. reported a annual revenue of 78.44 Million USD in annual revenue 2021, down -65.52% from previous year.
  • Esperion Therapeutics, Inc. reported a quarterly revenue of 137.73 Million USD for 2024 Q1, up 327.09% from previous quarter.
  • Esperion Therapeutics, Inc. reported a quarterly revenue of 116.33 Million USD for 2023 FY, up 54.14% from previous quarter.

Annual Revenue Chart of Esperion Therapeutics, Inc. (2023 - 1999)

Historical Annual Revenue of Esperion Therapeutics, Inc. (2023 - 1999)

Year Revenue Revenue Growth
2023 116.33 Million USD 54.14%
2022 75.47 Million USD -3.79%
2021 78.44 Million USD -65.52%
2020 227.54 Million USD 53.37%
2019 148.36 Million USD -19.57%
2018 184.47 Million USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD -100.0%
2013 4.97 Billion USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2002 - USD 0.0%
2001 - USD -100.0%
2000 2000.00 USD 0.0%
1999 - USD 0.0%

Peer Revenue Comparison of Esperion Therapeutics, Inc.

Name Revenue Revenue Difference
Thermo Fisher Scientific Inc. 42.85 Billion USD 99.729%
Dynavax Technologies Corporation 232.28 Million USD 49.917%
Illumina, Inc. 4.5 Billion USD 97.417%
IQVIA Holdings Inc. 14.98 Billion USD 99.224%
Biogen Inc. 9.83 Billion USD 98.817%
Iovance Biotherapeutics, Inc. 1.18 Million USD -9684.188%
Mettler-Toledo International Inc. 3.78 Billion USD 96.929%
Sarepta Therapeutics, Inc. 1.24 Billion USD 90.643%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 80.851%
Waters Corporation 2.95 Billion USD 96.065%
Perrigo Company plc 4.65 Billion USD 97.501%
uniQure N.V. 15.84 Million USD -634.293%
Agios Pharmaceuticals, Inc. 26.82 Million USD -333.71%
Amicus Therapeutics, Inc. 399.35 Million USD 70.87%
Atara Biotherapeutics, Inc. 8.57 Million USD -1256.981%
bluebird bio, Inc. 29.49 Million USD -294.393%
Cara Therapeutics, Inc. 20.96 Million USD -454.817%
Imunon, Inc. - USD -Infinity%
Myriad Genetics, Inc. 678.4 Million USD 82.852%
Neurocrine Biosciences, Inc. 1.88 Billion USD 93.835%
Nektar Therapeutics 90.12 Million USD -29.085%
Editas Medicine, Inc. 78.12 Million USD -48.911%
Verastem, Inc. - USD -Infinity%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 99.921%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Heron Therapeutics, Inc. 127.04 Million USD 8.43%
Unity Biotechnology, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 95.191%
Sangamo Therapeutics, Inc. 176.23 Million USD 33.988%
Evolus, Inc. 202.08 Million USD 42.433%
Adicet Bio, Inc. - USD -Infinity%
Aclaris Therapeutics, Inc. 31.24 Million USD -272.281%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 99.113%
FibroGen, Inc. 147.75 Million USD 21.264%
Agilent Technologies, Inc. 6.83 Billion USD 98.297%
OPKO Health, Inc. 863.49 Million USD 86.528%
Homology Medicines, Inc. -6.65 Million USD 1849.12%
Geron Corporation 237 Thousand USD -48986.076%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 93.637%
Exelixis, Inc. 1.83 Billion USD 93.644%
Viking Therapeutics, Inc. - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 36.27 Million USD -220.7%
Zoetis Inc. 8.54 Billion USD 98.638%
Axsome Therapeutics, Inc. 270.6 Million USD 57.009%
Abeona Therapeutics Inc. 3.5 Million USD -3223.829%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 98.821%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 85.23%
Corcept Therapeutics Incorporated 482.37 Million USD 75.883%
Halozyme Therapeutics, Inc. 829.25 Million USD 85.971%
Blueprint Medicines Corporation 249.38 Million USD 53.351%
Insmed Incorporated 305.2 Million USD 61.884%
TG Therapeutics, Inc. 233.66 Million USD 50.213%
Incyte Corporation 3.69 Billion USD 96.852%
Emergent BioSolutions Inc. 1.04 Billion USD 88.913%